Lucid Diagnostics (LUCD) News Today $1.28 -0.01 (-0.39%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.29 +0.00 (+0.31%) As of 05/2/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025April 30, 2025 | prnewswire.comLucid Diagnostics’ EsoGuard DNA Test shows cancer detection efficacy in studyApril 26, 2025 | markets.businessinsider.comLucid Diagnostics Reports Positive Data for EsoGuard in Study of Asymptomatic PatientsApril 24, 2025 | theglobeandmail.comLucid reports encouraging results from EsoGuard studyApril 24, 2025 | msn.comNCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERDApril 24, 2025 | prnewswire.comAscendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock PriceAscendiant Capital Markets boosted their price target on shares of Lucid Diagnostics from $7.00 to $7.50 and gave the stock a "buy" rating in a report on Monday.April 23, 2025 | marketbeat.comLucid Diagnostics price target raised to $7.50 from $7 at AscendiantApril 22, 2025 | markets.businessinsider.comLucid Diagnostics (NASDAQ:LUCD) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research note on Friday.April 13, 2025 | marketbeat.comLucid Diagnostics Closes $16.1 Million Public OfferingApril 11, 2025 | tipranks.comLucid Diagnostics Announces Closing of Public Offering of Common StockApril 11, 2025 | prnewswire.comLucid Diagnostics 12.5M share Spot Secondary priced at $1.20April 10, 2025 | markets.businessinsider.comLucid Diagnostics announces common stock offering, no amount givenApril 10, 2025 | markets.businessinsider.comLucid Diagnostics stock falls after pricing capital raise of $15M via stock offeringApril 10, 2025 | msn.comLucid Diagnostics Stock Sinks After-Hours On Equity Raise, But Retail Dives In AnywayApril 10, 2025 | msn.comLucid Diagnostics Announces Pricing of Public Offering of Common StockApril 9, 2025 | prnewswire.comLucid Diagnostics Announces Pricing of Public Offering of Common StockApril 9, 2025 | prnewswire.comLucid Diagnostics Announces Proposed Public Offering of Common StockApril 9, 2025 | prnewswire.comLucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare ConferenceApril 3, 2025 | prnewswire.comLucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest UpdateLucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) was the recipient of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 1,220,000 shares, a decrease of 31.8% from the February 28th total of 1,790,000 shares. Approximately 3.8% of the company's stock are sold short. Based on an average daily volume of 601,900 shares, the short-interest ratio is currently 2.0 days.March 31, 2025 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Lucid Diagnostics (NASDAQ:LUCD)Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $2.00 price target on shares of Lucid Diagnostics in a report on Wednesday.March 27, 2025 | marketbeat.comLucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection TechnologyMarch 27, 2025 | prnewswire.comLucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | seekingalpha.comLucid Diagnostics Earnings Call Highlights Growth and ChallengesMarch 25, 2025 | tipranks.comLucid Diagnostics (NASDAQ:LUCD) Given New $3.00 Price Target at Needham & Company LLCNeedham & Company LLC increased their price objective on shares of Lucid Diagnostics from $2.50 to $3.00 and gave the company a "buy" rating in a research note on Monday.March 25, 2025 | marketbeat.comLucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Expectations By $0.06 EPSLucid Diagnostics (NASDAQ:LUCD - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06).March 25, 2025 | marketbeat.comLucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | insidermonkey.comLucid Diagnostics reports Q4 EPS (19c) vs (23c) last yearMarch 24, 2025 | markets.businessinsider.comLucid Diagnostics Inc (LUCD) Q4 2024 Earnings Report Preview: What To ExpectMarch 22, 2025 | finance.yahoo.comNeedham maintains Buy on Lucid Diagnostics, $2.50 targetMarch 22, 2025 | uk.investing.comLucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer ScreeningMarch 20, 2025 | prnewswire.comBTIG Keeps Their Buy Rating on Lucid Diagnostics (LUCD)March 18, 2025 | markets.businessinsider.comLucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed PublicationMarch 18, 2025 | prnewswire.comLucid Diagnostics (LUCD) Expected to Announce Earnings on MondayLucid Diagnostics (NASDAQ:LUCD) will be releasing earnings before the market opens on Monday, March 24, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=673713)March 17, 2025 | marketbeat.comShort Interest in Lucid Diagnostics Inc. (NASDAQ:LUCD) Rises By 72.1%Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,790,000 shares, a growth of 72.1% from the February 13th total of 1,040,000 shares. Based on an average daily trading volume, of 576,100 shares, the days-to-cover ratio is presently 3.1 days. Currently, 5.6% of the company's shares are sold short.March 16, 2025 | marketbeat.comLucid Diagnostics secures first positive insurance coverage for EsoGuard testMarch 13, 2025 | markets.businessinsider.comLucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA TestMarch 13, 2025 | prnewswire.comLucid Diagnostics (NASDAQ:LUCD) Trading Down 14.4% - Here's WhyLucid Diagnostics (NASDAQ:LUCD) Trading Down 14.4% - Time to Sell?March 11, 2025 | marketbeat.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025March 10, 2025 | prnewswire.comLucid Diagnostics Announces Closing of $15.3 Million Registered Direct OfferingMarch 5, 2025 | prnewswire.comLucid Diagnostics stock dips on $15.3M share offeringMarch 4, 2025 | msn.comLucid Diagnostics Announces $15.3 Million Registered Direct OfferingMarch 4, 2025 | prnewswire.comLucid Diagnostics Inc. (NASDAQ:LUCD) Sees Significant Increase in Short InterestLucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 1,040,000 shares, a growth of 95.2% from the January 31st total of 532,700 shares. Based on an average trading volume of 531,800 shares, the days-to-cover ratio is presently 2.0 days. Currently, 4.3% of the company's stock are short sold.March 2, 2025 | marketbeat.comRenowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard in At-Risk Patients without Symptomatic GERDFebruary 28, 2025 | finanznachrichten.deRenowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERDFebruary 27, 2025 | prnewswire.comLucid Diagnostics regains Nasdaq complianceFebruary 26, 2025 | markets.businessinsider.comLucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 25, 2025 | prnewswire.comLucid Diagnostics entered first concierge medicine contract with LEAA HealthFebruary 20, 2025 | markets.businessinsider.comLucid Diagnostics Executes First Concierge Medicine Contract with LEAA HealthFebruary 20, 2025 | prnewswire.comLucid Diagnostics stock hits 52-week high at $1.5 amid growth optimismFebruary 14, 2025 | msn.comLucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFebruary 6, 2025 | prnewswire.com Get Lucid Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter. Email Address LUCD Media Mentions By Week LUCD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LUCD News Sentiment▼0.000.73▲Average Medical News Sentiment LUCD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LUCD Articles This Week▼12▲LUCD Articles Average Week Get Lucid Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KIDS News BBNX News TMCI News CLPT News DCTH News NPCE News SMLR News TCMD News NNOX News STIM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LUCD) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LUCD Stock Free LUCD Stock Alerts